| Date | Time | Source | Headline | Symbol | Company |
| 05/08/2024 | 1:05PM | iHub Newswire | FeaturedElement79 Gold Corp Successfully Closes Maverick Springs Option Agreement | | |
| 05/06/2024 | 7:14AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 04/17/2024 | 7:00AM | PR Newswire (US) | BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting | NASDAQ:BLRX | BioLineRx Ltd |
| 03/04/2024 | 7:47AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 02/28/2024 | 7:08AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 02/16/2024 | 7:07AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 01/08/2024 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:BLRX | BioLineRx Ltd |
| 12/29/2023 | 4:20PM | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:BLRX | BioLineRx Ltd |
| 12/29/2023 | 4:15PM | Edgar (US Regulatory) | Form F-3 - Registration statement by foreign private issuers | NASDAQ:BLRX | BioLineRx Ltd |
| 12/21/2023 | 7:05AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 12/12/2023 | 7:07AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 11/20/2023 | 7:03AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 11/20/2023 | 6:25AM | IH Market News | Monday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and more | NASDAQ:BLRX | BioLineRx Ltd |
| 11/01/2023 | 7:43AM | PR Newswire (Canada) | BioLineRx a conclu un accord de licence exclusive pour le motixafortide en Asie, sous les conseils de MSQ Ventures | NASDAQ:BLRX | BioLineRx Ltd |
| 10/31/2023 | 9:00AM | PR Newswire (US) | BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures | NASDAQ:BLRX | BioLineRx Ltd |
| 10/31/2023 | 9:00AM | PR Newswire (Canada) | BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures | NASDAQ:BLRX | BioLineRx Ltd |
| 10/26/2023 | 2:18PM | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | NASDAQ:BLRX | BioLineRx Ltd |
| 10/18/2023 | 5:07PM | AllPennyStocks.com | New Collaboration Could Revolutionize Treatment of Chronic Spinal Cord Injuries | NASDAQ:BLRX | BioLineRx Ltd |
| 10/12/2023 | 7:14AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 09/28/2023 | 7:11AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 09/11/2023 | 7:07AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 09/11/2023 | 7:00AM | PR Newswire (US) | BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma | NASDAQ:BLRX | BioLineRx Ltd |
| 08/30/2023 | 7:16AM | IH Market News | Wednesday’s Wall Street Highlights: Ambarella, Alphabet, Toyota, HP Inc, Vinfast, and more | NASDAQ:BLRX | BioLineRx Ltd |
| 08/30/2023 | 7:15AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 08/30/2023 | 6:45AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 08/08/2023 | 5:25PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 07/17/2023 | 7:10AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 06/23/2023 | 4:17PM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:BLRX | BioLineRx Ltd |
| 05/24/2023 | 7:07AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:BLRX | BioLineRx Ltd |
| 04/25/2023 | 7:08AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:BLRX | BioLineRx Ltd |